SDGR Stock Recent News

Besides Wall Street's top -and-bottom-line estimates for Schrodinger, Inc. (SDGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.

We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.

Customers in the biopharma industry are cutting spending, creating a soft demand environment for Schrodinger's software and drug discovery services. Despite the recent share price spike, Schrodinger's valuation is still low when accounting for all of the company's assets (cash, equity, milestones, royalties, software business). While Schrodinger's stock should do well long-term, growth is likely to remain weak in the near term and losses will remain high while the company invests in its proprietary pipeline.

Schrödinger helps drugmakers discover high-quality leads for drug development. It has a star-studded cast of collaborators already, but it isn't growing much.

Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Ramy Farid - President and Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies LLC Malcolm Hoffman - BMO Capital Markets Michael Ryskin - Bank of America Securities, Inc. Matthew Hewitt - Craig-Hallum Capital Group Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs & Co. Operator Welcome to Schrödinger's Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today's call.

When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spent less time around Microsoft's business, the billionaire has significantly diversified his investment portfolio.

This company uses AI to improve drug discovery for all of the 20 biggest biopharmaceutical companies. Even the most pessimistic analyst thinks the stock could jump nearly 32% over the next 12 months.

The transformative power of artificial intelligence ( AI ) — with regards to drug makers and banks to oil companies to every firm that carries out intensive sales activities — is widely known. Yet in spite of all of these points, it appears that the Street — which has been much more focused on a one percentage point change in bond rates lately than the revolutionary power of AI — is giving very few AI stocks the credit they deserve.

Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship product, Maestro, integrates various proprietary software tools for molecular modeling and simulation. SDGR has experienced significant growth and has established itself as the industry standard in the AI revolution in healthcare.